Jubilant Ingrevia Reports Strong Q4 Results Amid Debt Collection Challenges

Jubilant Ingrevia, a midcap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The results indicate a notable shift in the company's financial metrics, with a revision in its score reflecting these changes.
The company has demonstrated a strong performance in several key areas. The operating profit to interest ratio reached its highest level at 11.16 times, showcasing an enhanced ability to manage interest payments effectively. Additionally, the profit before tax (PBT) recorded a significant increase, reaching Rs 86.15 crore, which is 60.8% higher than the average of the previous four quarters. Similarly, profit after tax (PAT) also saw a substantial rise, amounting to Rs 69.38 crore, marking a 58.1% growth over the prior average.

Operating profit (PBDIT) hit a peak of Rs 138.29 crore, and the operating profit margin improved to 13.09%, indicating enhanced efficiency. Furthermore, earnings per share (EPS) reached Rs 4.39, reflecting increased profitability for shareholders.

However, the company faced challenges with its debtors turnover ratio, which was recorded at its lowest in the last five half-yearly periods, suggesting a slower pace in settling debts.

For more insights on Jubilant Ingrevia's financial trends, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.